<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594425</url>
  </required_header>
  <id_info>
    <org_study_id>PC TA202B/06</org_study_id>
    <nct_id>NCT00594425</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter study will be divided into 2 phases. The first phase will be an open label,
      dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled,
      parallel-group, dose-response phase. The second phase will only start if the first phase
      succeeds in establishing well tolerated dose(s). Patients with moderate to severe acne
      vulgaris in the face will be included.The results from part 2 has been presented in the
      result section.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the second part: All patients will receive 4 PDT sessions 2 weeks apart using a light
      dose of 37 J/cm2. One treatment group will receive vehicle cream, while the other 2 groups
      will receive MAL cream with a concentration of 40 mg/g and 80 mg/g, respectively. The MAL and
      vehicle cream will be applied in a thin layer on clean skin and left for 1.5 hours under
      occlusion before illumination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</measure>
    <time_frame>3 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percentage Change in Facial Non Inflammatory Lesion Counts From Baseline</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in Total Lesion Counts From Baseline</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients Rated as Clear or Almost Clear at 12 Weeks After Last Treatment</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</measure>
    <time_frame>immediately after illumination-first treatment</time_frame>
    <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain</measure>
    <time_frame>immediately after second treatment</time_frame>
    <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</measure>
    <time_frame>immediately after third treatment</time_frame>
    <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</measure>
    <time_frame>immediately after illumination-fourth treatment treatment</time_frame>
    <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Erythema After First Treatment</measure>
    <time_frame>immediately after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Erythema After First Treatment</measure>
    <time_frame>2 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Erythema After Second Treatment</measure>
    <time_frame>immediately after second treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Erythema After Third Treatment</measure>
    <time_frame>immediately after third treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Erythema After Fourth Treatment</measure>
    <time_frame>immediately after fourth treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema After First Treatment</measure>
    <time_frame>immediately after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema 2 Days After First Treatment</measure>
    <time_frame>2 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema 7 Days After First Treatment</measure>
    <time_frame>7 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema After Second Treatment</measure>
    <time_frame>immediately after second treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema After Third Treatment</measure>
    <time_frame>immediately after third treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Severe Erythema After Fourth Treatment</measure>
    <time_frame>immediately after fourth treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</measure>
    <time_frame>2 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</measure>
    <time_frame>2 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</measure>
    <time_frame>2 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</measure>
    <time_frame>2 days after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</measure>
    <time_frame>2 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</measure>
    <time_frame>2 weeks after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</measure>
    <time_frame>6 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</measure>
    <time_frame>12 weeks after last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDT using MAL concentration A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDT using MAL concentration B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PDT using Placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyl aminolevulinate (MAL) PDT</intervention_name>
    <description>Cream application followed by illumination with red light</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male patients, age 15 to 40 years with moderate to severe facial acne
             vulgaris (IGA score 3-4).

          2. Patients with skin type I to IV (Fitzpatrick).

          3. Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the
             face excluding lesions on the nose and in the peri-ocular area.

          4. Patients with up to 200 noninflammatory lesions (open and closed comedones) on the
             face.

          5. Patients with no more than 2 nodular lesions on the face.

          6. Patients who are surgically sterile, postmenopausal, abstinent, or willing to use an
             adequate means of contraception including birth control pills, or barrier methods and
             spermicide for at least 14 days prior to Day 0. Patients using birth control pills
             must have used the same product and dose for at least 6 months and must agree to stay
             with the same product and dose for an additional 6 months.

          7. Patients must be willing and capable of following study instructions to the extent and
             degree required by the protocol.

          8. Patients must sign the approved informed consent form prior to any study procedures.

          9. Patients must be willing to be photographed. Patients must be willing to sign a
             photography consent form.

        Exclusion Criteria:

          1. Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.

          2. Participation in other clinical studies either concurrently or within the last 30
             days.

          3. Patients who have a condition or who are in a situation, which, in the investigator's
             opinion, may put the patient at risk, may confound the study results, or may interfere
             with the patient's participation in the study.

          4. Clinically significant sensitivity to visible light, or has porphyria or porphyrin
             sensitivity.

          5. Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the
             last 30 days.

          6. Patients with a washout period for topical treatments for their acne of less than 14
             days. Medicated cleansers may be used during the washout period and stopped before the
             treatment.

          7. Patients with a washout period for oral antibiotics for treatment of their acne of
             less than 1 month.

          8. Patients with a washout period for oral isotretinoin of less than 6 months.

          9. Patients with a beard or other facial hair that might interfere with study
             assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Pariser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DuPage Medical Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Research Corp</name>
      <address>
        <city>Clinton Twp</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment &amp; Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501-1604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <results_first_submitted>March 14, 2013</results_first_submitted>
  <results_first_submitted_qc>August 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2013</results_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient entered: February 07, 2007 Last patient last visit (12 week follow-up: July 07, 2008 Last patient last visit (24 week follow-up: September 22, 2008 15 medical derm clinics</recruitment_details>
      <pre_assignment_details>Washout periods for prior acne treatment: 14 days for any topical treatment (except medicated cleansers), 1 month for oral antibiotics; 6 months for oral isotretinoin. Patients using birth control pills must have used the same product and dose for at least 6 months and had to agree to stay with the same product and dose for an additional 6 months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>40 mg/g MAL PDT</title>
        </group>
        <group group_id="P2">
          <title>80 mg/g MAL PDT</title>
        </group>
        <group group_id="P3">
          <title>Vehicle PDT</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>40 mg/g MAL PDT</title>
        </group>
        <group group_id="B2">
          <title>80 mg/g MAL PDT</title>
        </group>
        <group group_id="B3">
          <title>Vehicle PDT</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.6" spread="5.24"/>
                    <measurement group_id="B2" value="20.2" spread="4.81"/>
                    <measurement group_id="B3" value="22.0" spread="5.00"/>
                    <measurement group_id="B4" value="21.3" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory lesion count</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" lower_limit="20" upper_limit="81"/>
                    <measurement group_id="B2" value="32.1" lower_limit="19" upper_limit="60"/>
                    <measurement group_id="B3" value="31.2" lower_limit="20" upper_limit="74"/>
                    <measurement group_id="B4" value="32.5" lower_limit="19" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non inflammatory lesion count</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" lower_limit="4" upper_limit="99"/>
                    <measurement group_id="B2" value="35.9" lower_limit="5" upper_limit="111"/>
                    <measurement group_id="B3" value="35.2" lower_limit="7" upper_limit="94"/>
                    <measurement group_id="B4" value="36.7" lower_limit="4" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment (IGA) Score</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IGA SCORE 3 (MODERATE ACNE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA SCORE 4 (SEVERE ACNE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin type</title>
          <description>The patients is scored according to a predefined description of 4 different skin types.
I White; very fair; red or blond hair; blue eyes; freckles Always burns, never tans
II White; fair; red or blond hair; blue, hazel or green eyes Usually burns, tans with difficulty
III Cream white; fair with any eye or hair color; very common Sometimes mild burn, gradually tans
IV Brown; typical Mediterranean Caucasian skin Rarely burns, tans with ease</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Fitzpatrick skin type score I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick skin type score II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick skin type score III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fitzpatrick skin type score IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
        <time_frame>3 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.5" spread="39,32" lower_limit="-89" upper_limit="42"/>
                    <measurement group_id="O2" value="-56.0" spread="44-34" lower_limit="-95" upper_limit="44"/>
                    <measurement group_id="O3" value="-40.5" spread="34-41" lower_limit="-100" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.0" lower_limit="-92" upper_limit="88"/>
                    <measurement group_id="O2" value="-69.5" lower_limit="-95" upper_limit="45"/>
                    <measurement group_id="O3" value="-52.0" lower_limit="-96" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percentage Change in Facial Non Inflammatory Lesion Counts From Baseline</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Median Percentage Change in Facial Non Inflammatory Lesion Counts From Baseline</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" lower_limit="-89" upper_limit="160"/>
                    <measurement group_id="O2" value="-48.0" lower_limit="-95" upper_limit="104"/>
                    <measurement group_id="O3" value="-38.0" lower_limit="-100" upper_limit="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
          <population>ITT population</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="8.34" upper_limit="28.51"/>
                    <measurement group_id="O2" value="14.58" lower_limit="7.25" upper_limit="27.17"/>
                    <measurement group_id="O3" value="11.54" lower_limit="5.40" upper_limit="22.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5288</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by center. No adjustment for multiple comparisons was done</method_desc>
            <param_type>% success rate</param_type>
            <param_value>5.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.97</ci_lower_limit>
            <ci_upper_limit>19.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7539</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by center. No adjustment for multiple comparisons was done</method_desc>
            <param_type>% success rate</param_type>
            <param_value>3.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.79</ci_lower_limit>
            <ci_upper_limit>16.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts</title>
          <population>ITT population</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.72" lower_limit="-14.45" upper_limit="-6.99"/>
                    <measurement group_id="O2" value="-9.27" lower_limit="-13.25" upper_limit="-5.3"/>
                    <measurement group_id="O3" value="-8.08" lower_limit="-11.8" upper_limit="-4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3236</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including center and baseline lesion count as a covariates. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Least squares mean</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.91</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6657</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including center and baseline lesion count as a covariates. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Least squares mean</param_type>
            <param_value>-1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.64</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in Total Lesion Counts From Baseline</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in Total Lesion Counts From Baseline</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40" lower_limit="-88" upper_limit="66"/>
                    <measurement group_id="O2" value="-54" lower_limit="-87" upper_limit="68"/>
                    <measurement group_id="O3" value="-37" lower_limit="-94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>Precentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients Rated as Clear or Almost Clear at 12 Weeks After Last Treatment</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients Rated as Clear or Almost Clear at 12 Weeks After Last Treatment</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
        <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
        <time_frame>immediately after illumination-first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
          <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
          <population>Safety</population>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.25" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain</title>
        <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
        <time_frame>immediately after second treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain</title>
          <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
          <population>Safety</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
        <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
        <time_frame>immediately after third treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
          <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
          <population>Safety</population>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
        <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
        <time_frame>immediately after illumination-fourth treatment treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain Using Visual Analouge Scale From 0 to 10, Were 0 Indicates no Pain and 10 Indicates Worst Pain.</title>
          <description>Measure was assessed on a Visual Analogue Scale from 0 to 10 cm</description>
          <population>Safety</population>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" lower_limit="0.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.50" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Erythema After First Treatment</title>
        <time_frame>immediately after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Erythema After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1"/>
                    <measurement group_id="O2" value="61.7"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Erythema After First Treatment</title>
        <time_frame>2 days after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Erythema After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="44.7"/>
                    <measurement group_id="O3" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Erythema After Second Treatment</title>
        <time_frame>immediately after second treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Erythema After Second Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="65.8"/>
                    <measurement group_id="O3" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Erythema After Third Treatment</title>
        <time_frame>immediately after third treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Erythema After Third Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4"/>
                    <measurement group_id="O2" value="71.1"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Erythema After Fourth Treatment</title>
        <time_frame>immediately after fourth treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Erythema After Fourth Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="63.1"/>
                    <measurement group_id="O3" value="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema After First Treatment</title>
        <time_frame>immediately after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.1"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema 2 Days After First Treatment</title>
        <time_frame>2 days after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema 2 Days After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema 7 Days After First Treatment</title>
        <time_frame>7 days after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema 7 Days After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema After Second Treatment</title>
        <time_frame>immediately after second treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema After Second Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema After Third Treatment</title>
        <time_frame>immediately after third treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema After Third Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Severe Erythema After Fourth Treatment</title>
        <time_frame>immediately after fourth treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Severe Erythema After Fourth Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</title>
        <time_frame>2 days after treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</title>
        <time_frame>2 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
        <time_frame>2 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="8.1"/>
                    <measurement group_id="O3" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hyperpigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</title>
        <time_frame>2 days after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
        <time_frame>2 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</title>
        <time_frame>2 weeks after first treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hypopigmentation After First Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
        <time_frame>6 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Success, Defined as Improvement of at Least 2 Grades From Baseline According to the IGA Scale Based on Facial Assessment</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="6.72" upper_limit="27.84"/>
                    <measurement group_id="O2" value="21.2" lower_limit="8.75" upper_limit="31.95"/>
                    <measurement group_id="O3" value="16.7" lower_limit="10.68" upper_limit="37.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7889</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel stratified by center. No adjustment for multiple comparisons was done</method_desc>
            <param_type>%success rate</param_type>
            <param_value>3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.16</ci_lower_limit>
            <ci_upper_limit>17.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8880</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test stratified by center. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Percent success</param_type>
            <param_value>5.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.15</ci_lower_limit>
            <ci_upper_limit>21.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
        <time_frame>12 weeks</time_frame>
        <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Facial Inflammatory (Nodules, Papules, and Pustules) Lesion Counts From Baseline</title>
          <population>PP population: excludes all patients with major protocol deviations (consists of the following types of events: Baseline inflammatory lesion count other than 20-100, received less that 4 treatments, primary efficacy criteria missing at week 12, insufficient primary efficacy follow up time, prohibited concomitant medication (retinoid).</population>
          <units>lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.95" lower_limit="-15.18" upper_limit="-6.72"/>
                    <measurement group_id="O2" value="-11.8" lower_limit="-16.65" upper_limit="-6.95"/>
                    <measurement group_id="O3" value="-10.62" lower_limit="-15.12" upper_limit="-6.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9151</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including center and baseline lesion count as a covariates. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Least squares mean</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.53</ci_lower_limit>
            <ci_upper_limit>5.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>H0: τ (Vehicle PDT) = τ (MAL PDT) versus HA: τ (Vehicle PDT) ≠ τ (MAL PDT)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7233</p_value>
            <p_value_desc>Priori threshold for statistical significance was 5%</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model including center and baseline lesion count as a covariates. No adjustment for multiple comparisons was done</method_desc>
            <param_type>Least squares mean</param_type>
            <param_value>-1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.81</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
        <time_frame>12 weeks after last treatment</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>40 mg/g MAL PDT</title>
          </group>
          <group group_id="O2">
            <title>80 mg/g MAL PDT</title>
          </group>
          <group group_id="O3">
            <title>Vehicle PDT</title>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Mild and Moderate Hypopigmentation After Last Treatment</title>
          <population>Safety</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>40 mg/g MAL PDT</title>
        </group>
        <group group_id="E2">
          <title>80 mg/g MAL PDT</title>
        </group>
        <group group_id="E3">
          <title>Vehicle PDT</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>APPLICATION SITE DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE SCAB</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE WARMTH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All data from the study are free for publication. However if publication of the results may endanger adequate patent protection for new principles,compounds,or formulations,Photocure has the right to decide when the results are free to be published. Before this agreed time, no data from the trial will be published, presented, or communicated, except to regulatory authorities and ethics committees. Both the investigators and Photocure will be given 30 days to review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Pariser MD</name_or_title>
      <organization>Virginia Clinical Research, Inc</organization>
      <phone>757-625-0151</phone>
      <email>dpariser@pariserderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

